Background: Despite the low recurrence rate of resected nonfunctional pancreatic neuroendocrine tumors (NF-pNETs), nearly all patients undergo long-term surveillance. A prediction model for recurrence may help select patients for less intensive surveillance or identify patients for adjuvant therapy. The objective of this study was to assess the external validity of a recently published model predicting recurrence within 5 years after surgery for NF-pNET in an international cohort. This prediction model includes tumor grade, lymph node status and perineural invasion as predictors. Methods: Retrospectively, data were collected from 7 international referral centers on patients who underwent resection for a grade 1-2 NF-pNET between 1992 and 20...
[Introduction] Pancreatic neuroendocrine neoplasms (PNEN) are rare tumours and well differentiated P...
Background/Aims Pancreatic Neuroendocrine Tumors (pan-NENs) represent an increasingly common indicat...
Background: Surgery represents the only curative treatment for stage I-III midgut neuroendocrine tum...
Background: Despite the low recurrence rate of resected nonfunctional pancreatic neuroendocrine tumo...
Objective: To develop a nomogram estimating the probability of recurrence free at 5 years after re...
OBJECTIVE: To develop a nomogram estimating the probability of recurrence free at 5 years after rese...
The aim of this study was to predict recurrence in patients with grade 1 or 2 nonfunctioning pancrea...
Background: The risk of recurrence after resection of non-metastatic gastro-entero-pancreatic neuroe...
Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/144243/1/jso24985_am.pdfhttps://deepbl...
Background: Identifying patients at risk for early recurrence (ER) following resection for pancreati...
none9noPurpose: Patients submitted to curative surgery for non-functioning pancreatic neuroendocrine...
textabstractBackground: Despite evidence of different malignant potentials, postoperative follow-up ...
BACKGROUND: Surgery with radical intent is the only potentially curative option for entero-pancreati...
Background: Recurrence of pancreatic neuroendocrine tumors (pNET) after surgery is common. Strategie...
BackgroundPatients with early-stage pancreatic neuroendocrine tumors (PNETs) may develop metastatic ...
[Introduction] Pancreatic neuroendocrine neoplasms (PNEN) are rare tumours and well differentiated P...
Background/Aims Pancreatic Neuroendocrine Tumors (pan-NENs) represent an increasingly common indicat...
Background: Surgery represents the only curative treatment for stage I-III midgut neuroendocrine tum...
Background: Despite the low recurrence rate of resected nonfunctional pancreatic neuroendocrine tumo...
Objective: To develop a nomogram estimating the probability of recurrence free at 5 years after re...
OBJECTIVE: To develop a nomogram estimating the probability of recurrence free at 5 years after rese...
The aim of this study was to predict recurrence in patients with grade 1 or 2 nonfunctioning pancrea...
Background: The risk of recurrence after resection of non-metastatic gastro-entero-pancreatic neuroe...
Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/144243/1/jso24985_am.pdfhttps://deepbl...
Background: Identifying patients at risk for early recurrence (ER) following resection for pancreati...
none9noPurpose: Patients submitted to curative surgery for non-functioning pancreatic neuroendocrine...
textabstractBackground: Despite evidence of different malignant potentials, postoperative follow-up ...
BACKGROUND: Surgery with radical intent is the only potentially curative option for entero-pancreati...
Background: Recurrence of pancreatic neuroendocrine tumors (pNET) after surgery is common. Strategie...
BackgroundPatients with early-stage pancreatic neuroendocrine tumors (PNETs) may develop metastatic ...
[Introduction] Pancreatic neuroendocrine neoplasms (PNEN) are rare tumours and well differentiated P...
Background/Aims Pancreatic Neuroendocrine Tumors (pan-NENs) represent an increasingly common indicat...
Background: Surgery represents the only curative treatment for stage I-III midgut neuroendocrine tum...